drugset / Trial / NCT00249977
Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan
Non-randomizedSingle-groupOpen-labelTreatment
Summary
1. To determine the safety and feasibility of administering Capecitabine with the combination of Cisplatin and Irinotecan. 2. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the combination of Cisplatin and Irinotecan. 3. To study the biologic effect of pyrimidine inhibition on DNA repair after camptothecin therapy.
Timeline
- Start
- 2003-04
- Primary completion
- 2007-08
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | — |
| Background | Irinotecan | Small molecule | 50 mg/m2 | — |